Background: The composition of the thrombus influences its retrievability by mechanical thrombectomy.

Purpose: Our study aimed to report on thrombi resistant to aspiration, regarding susceptibility vessel sign and histologic composition.

Methods: This observational study was based on a prospective database of acute anterior circulation ischemic strokes treated by mechanical thrombectomy. Endovascular first-line strategy was aspiration and in case of failure, combined therapy-rescue was performed. The positivity of susceptibility vessel sign (SVS+) or its negativity (SVS-) was assessed on T2* sequences. The thrombus composition was analyzed with hematoxylin eosin staining.

Results: Histological analysis was performed on 102 clots. Thrombi with SVS- were significantly richer in fibrin/platelets, p = 0.04. Out of 210 mechanical thrombectomy, aspiration first pass strategy was performed in 131/210 (62%) patients. Combined therapy-rescue was needed in 37% of aspiration first pass strategy cases ( = 131). Clots retrieved combined therapy-rescue were richer in fibrin/platelets 63.9% versus 50.8% for aspiration first pass strategy, p = 0.03. Logistic regression analysis showed that fibrin/platelet-poor clots (<60%) were significantly more likely to be recanalized by aspiration first pass strategy compared to fibrin/platelet-rich clots (>60%) that were more likely recanalized by combined therapy-rescue after aspiration first pass strategy failure (OR = 3.5; 95% CI = 1.2-10.8; p = 0.0054).

Conclusions: Our results confirm that SVS- clots are rich in fibrin/platelets and suggest that these "white clots" are less likely to be retrieved by aspiration alone and more often require the use of combined therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1747493020986626DOI Listing

Publication Analysis

Top Keywords

combined therapy-rescue
16
aspiration pass
16
pass strategy
16
susceptibility vessel
12
vessel sign
12
mechanical thrombectomy
8
richer fibrin/platelets
8
aspiration
7
strategy
5
combined
5

Similar Publications

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy.

View Article and Find Full Text PDF

Background: The composition of the thrombus influences its retrievability by mechanical thrombectomy.

Purpose: Our study aimed to report on thrombi resistant to aspiration, regarding susceptibility vessel sign and histologic composition.

Methods: This observational study was based on a prospective database of acute anterior circulation ischemic strokes treated by mechanical thrombectomy.

View Article and Find Full Text PDF

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Cochrane Database Syst Rev

January 2017

Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.

Background: Cochrane systematic reviews show that systemic postnatal corticosteroids reduce the risk of bronchopulmonary dysplasia (BPD) in preterm infants. However, corticosteroids have also been associated with an increased risk of neurodevelopmental impairment. It is unknown whether these beneficial and adverse effects are modulated by differences in corticosteroid treatment regimens.

View Article and Find Full Text PDF

Background: Evidence to guide rescue therapy in refractory Kawasaki disease (KD) is lacking. The aim of this study was to determine the most important variables in predicting non-response to rescue therapy in refractory KD.

Methods: We retrospectively analyzed 171 patients diagnosed with refractory KD resistant to initial i.

View Article and Find Full Text PDF

mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms.

Sci Transl Med

October 2013

Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada.

ZMAb is a promising treatment against Ebola virus (EBOV) disease that has been shown to protect 50% (two of four) of nonhuman primates (NHPs) when administered 2 days post-infection (dpi). To extend the treatment window and improve protection, we combined ZMAb with adenovirus-vectored interferon-α (Ad-IFN) and evaluated efficacy in EBOV-infected NHPs. Seventy-five percent (three of four) and 100% (four of four) of cynomolgus and rhesus macaques survived, respectively, when treatment was initiated after detection of viremia at 3 dpi.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!